Non-Small Cell Lung Carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Promoter methylation of Ras association domain family (RASSF1A) and short stature homeobox 2 (SHOX2) was examined in bronchoalveolar lavage (BAL) from 117 NSCLC patients treated with chemotherapy.
|
31839603 |
2020 |
Malignant neoplasm of urinary bladder
|
0.400 |
Biomarker
|
disease |
BEFREE |
RASSF1A gene transfected the bladder cancer cells by lipofectamine.
|
31500788 |
2019 |
Malignant neoplasm of urinary bladder
|
0.400 |
PosttranslationalModification
|
disease |
BEFREE |
Three of the strong evidence associations involve RASSF1 methylation on bladder cancer risk (OR = 18.46; 95% CI: 12.69-26.85; I<sup>2</sup> = 0%), MGMT methylation on NSCLC (OR = 4.25; 95% CI: 2.83-6.38; I<sup>2</sup> = 22.4%) and RARB methylation on prostate cancer (OR = 6.87; 95% CI: 4.68-10.08; I<sup>2</sup> = 0%).
|
31202904 |
2019 |
Bladder Neoplasm
|
0.400 |
Biomarker
|
disease |
BEFREE |
RASSF1A gene transfected the bladder cancer cells by lipofectamine.
|
31500788 |
2019 |
Bladder Neoplasm
|
0.400 |
PosttranslationalModification
|
disease |
BEFREE |
Three of the strong evidence associations involve RASSF1 methylation on bladder cancer risk (OR = 18.46; 95% CI: 12.69-26.85; I<sup>2</sup> = 0%), MGMT methylation on NSCLC (OR = 4.25; 95% CI: 2.83-6.38; I<sup>2</sup> = 22.4%) and RARB methylation on prostate cancer (OR = 6.87; 95% CI: 4.68-10.08; I<sup>2</sup> = 0%).
|
31202904 |
2019 |
Non-Small Cell Lung Carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
The AUC of the SROC was 0.9989, calculated through Moses's model for RASSF1A promoter hypermethylation as a biomarker in diagnosis of NSCLC.
|
31342946 |
2019 |
Non-Small Cell Lung Carcinoma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Role of the YAP-1 Transcriptional Target cIAP2 in the Differential Susceptibility to Chemotherapy of Non-Small-Cell Lung Cancer (NSCLC) Patients with Tumor RASSF1A Gene Methylation from the Phase 3 IFCT-0002 Trial.
|
31766357 |
2019 |
Non-Small Cell Lung Carcinoma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
The overexpression of circ_0078767 and RASSF1A or the underexpression of miR-330-3p significantly suppressed NSCLC cell viability, cell cycle progression and invasion while also significantly promoting cell apoptosis.
|
30507050 |
2019 |
Non-Small Cell Lung Carcinoma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Three of the strong evidence associations involve RASSF1 methylation on bladder cancer risk (OR = 18.46; 95% CI: 12.69-26.85; I<sup>2</sup> = 0%), MGMT methylation on NSCLC (OR = 4.25; 95% CI: 2.83-6.38; I<sup>2</sup> = 22.4%) and RARB methylation on prostate cancer (OR = 6.87; 95% CI: 4.68-10.08; I<sup>2</sup> = 0%).
|
31202904 |
2019 |
Non-Small Cell Lung Carcinoma
|
0.400 |
PosttranslationalModification
|
disease |
BEFREE |
The overall analysis result indicated that RASSF1A methylation had no statistically significant effects on OS of NSCLC patients (HR = 1.28; 95% CI 0.86-1.70), which were confirmed by the subgroup analysis.
|
30764677 |
2019 |
Malignant neoplasm of lung
|
0.400 |
PosttranslationalModification
|
disease |
BEFREE |
However, the sensitivity analysis indicated that RASSF1A methylation from lung cancer tissues was significantly associated with lower OS (HR = 1.24; 95% CI 1.04-1.45).
|
30764677 |
2019 |
Malignant neoplasm of lung
|
0.400 |
Biomarker
|
disease |
BEFREE |
RASSF1A, a tumor suppressor gene, is frequently inactivated in lung cancer leading to a YAP-dependent epithelial-mesenchymal transition (EMT).
|
30979377 |
2019 |
Malignant neoplasm of lung
|
0.400 |
PosttranslationalModification
|
disease |
BEFREE |
We find that lung cancer cells with RASSF1A promoter methylation display constitutive nuclear YAP1 accumulation and expression of prolyl 4-hydroxylase alpha-2 (P4HA2) which increases collagen deposition.
|
31268606 |
2019 |
Adenocarcinoma
|
0.400 |
PosttranslationalModification
|
group |
BEFREE |
RASSF1A promoter methylation was associated with tumor grade (grade 3-4 vs 1-2: OR 2.31, 95% CI 1.12-4.77, P = 0.023), lymph node metastasis (yes vs no: OR 2.97, 95% CI 1.60-5.52, P = 0.001), tumor histology (squamous cell carcinoma vs adenocarcinoma: OR 0.49, 95% CI 0.22-1.08, P = 0.076), and HPV infection (positive vs negative: OR 0.45, 95% CI 0.28-0.73, P = 0.001).
|
29288321 |
2018 |
Malignant neoplasm of urinary bladder
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Next, hmDNA levels (RASSF1A qMSP) in stored urine samples of patients suffering from bladder cancer (n = 10) or non-small cell lung cancer (NSCLC; n = 10) were measured at day 0 and 7 upon storage with and without the addition of 40mM EDTA and/or 20 μl/ml Penicillin Streptomycin (PenStrep) at RT and 4°C.
|
30142219 |
2018 |
Bladder Neoplasm
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Next, hmDNA levels (RASSF1A qMSP) in stored urine samples of patients suffering from bladder cancer (n = 10) or non-small cell lung cancer (NSCLC; n = 10) were measured at day 0 and 7 upon storage with and without the addition of 40mM EDTA and/or 20 μl/ml Penicillin Streptomycin (PenStrep) at RT and 4°C.
|
30142219 |
2018 |
Non-Small Cell Lung Carcinoma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Next, hmDNA levels (RASSF1A qMSP) in stored urine samples of patients suffering from bladder cancer (n = 10) or non-small cell lung cancer (NSCLC; n = 10) were measured at day 0 and 7 upon storage with and without the addition of 40mM EDTA and/or 20 μl/ml Penicillin Streptomycin (PenStrep) at RT and 4°C.
|
30142219 |
2018 |
Non-Small Cell Lung Carcinoma
|
0.400 |
PosttranslationalModification
|
disease |
BEFREE |
RASSF1 hypermethylation was frequent in tumors and most prominent in NET making it an auxiliary marker for separation of NSCLC and NET.
|
29851970 |
2018 |
Lung Neoplasms
|
0.400 |
Biomarker
|
group |
BEFREE |
RASSF1A deficiency profoundly enhanced the development of K-RAS-driven lung tumors <i>in vivo</i> Analysis of these tumors showed loss of RASSF1A-uncoupled RAS from the proapoptotic Hippo pathway as expected.
|
29735543 |
2018 |
Malignant neoplasm of lung
|
0.400 |
Biomarker
|
disease |
BEFREE |
L1RE1 in combination with either RARB or RASSF1 could function as biomarkers for separating lung cancer and non-cancerous tissue and could be useful for samples of limited size such as biopsies.
|
29851970 |
2018 |
Malignant neoplasm of urinary bladder
|
0.400 |
PosttranslationalModification
|
disease |
BEFREE |
There was a significant relationship between the methylation of the RASSF1A gene promoter and bladder cancer.
|
28207521 |
2017 |
Bladder Neoplasm
|
0.400 |
PosttranslationalModification
|
disease |
BEFREE |
There was a significant relationship between the methylation of the RASSF1A gene promoter and bladder cancer.
|
28207521 |
2017 |
Non-Small Cell Lung Carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
The loss-of-function of DNA methyltransferase 1 by siRNA impairs the growth of non-small cell lung cancer with alleviated side effects via reactivation of RASSF1A and APC <i>in vitro</i> and <i>vivo</i>.
|
28938637 |
2017 |
Non-Small Cell Lung Carcinoma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
There is a better correlation between the expression of RASSF1A and SIRT6 in NSCLC tissues, and the detection of their expression is of great significance in the judgement of clinicopathological features and prognosis of NSCLC patients.
|
29204192 |
2017 |
Malignant neoplasm of lung
|
0.400 |
Biomarker
|
disease |
BEFREE |
The purpose of the study was to explore the application of artificial neural network model in the auxiliary diagnosis of lung cancer and compare the effects of back-propagation (BP) neural network with Fisher discrimination model for lung cancer screening by the combined detections of four biomarkers of p16, RASSF1A and FHIT gene promoter methylation levels and the relative telomere length.
|
27766520 |
2017 |